132 related articles for article (PubMed ID: 9950900)
21. Low-Dose Endothelial Monocyte-Activating Polypeptide-II Induces Blood-Tumor Barrier Opening Via the cAMP/PKA/Rac1 Pathway.
Li Z; Liu XB; Liu YH; Xue YX; Liu J; Teng H; Xi Z; Yao YL
J Mol Neurosci; 2016 Feb; 58(2):153-61. PubMed ID: 26358039
[TBL] [Abstract][Full Text] [Related]
22. Low-Dose Endothelial Monocyte-Activating Polypeptide-II Increases Blood-Tumor Barrier Permeability by Activating the RhoA/ROCK/PI3K Signaling Pathway.
Li Z; Liu XB; Liu YH; Xue YX; Liu J; Teng H; Xi Z; Yao YL
J Mol Neurosci; 2016 Jun; 59(2):193-202. PubMed ID: 26521255
[TBL] [Abstract][Full Text] [Related]
23. Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma.
Lans TE; ten Hagen TL; van Horssen R; Wu PC; van Tiel ST; Libutti SK; Alexander HR; Eggermont AM
Ann Surg Oncol; 2002 Oct; 9(8):812-9. PubMed ID: 12374666
[TBL] [Abstract][Full Text] [Related]
24. EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury.
Nührenberg TG; Langwieser N; Schwarz JB; Hou Y; Frank P; Sorge F; Matschurat S; Seidl S; Kastrati A; Schömig A; Clauss MA; Zohlnhöfer D
Cardiovasc Res; 2008 Feb; 77(3):580-9. PubMed ID: 18029408
[TBL] [Abstract][Full Text] [Related]
25. Heparan sulfate regulates the antiangiogenic activity of endothelial monocyte-activating polypeptide-II at acidic pH.
Chang SY; Ko HJ; Heo TH; Kang CY
Mol Pharmacol; 2005 May; 67(5):1534-43. PubMed ID: 15710745
[TBL] [Abstract][Full Text] [Related]
26. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
[TBL] [Abstract][Full Text] [Related]
27. Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells.
Liu J; Liu L; Xue Y; Meng F; Li S; Wang P; Liu Y
Biochem Pharmacol; 2014 Jun; 89(4):477-89. PubMed ID: 24792437
[TBL] [Abstract][Full Text] [Related]
28. Pro-EMAP II is not primarily cleaved by caspase-3 and -7.
Zhang FR; Schwarz MA
Am J Physiol Lung Cell Mol Physiol; 2002 Jun; 282(6):L1239-44. PubMed ID: 12003779
[TBL] [Abstract][Full Text] [Related]
29. Cell proliferation and migration are modulated by Cdk-1-phosphorylated endothelial-monocyte activating polypeptide II.
Schwarz MA; Thornton J; Xu H; Awasthi N; Schwarz RE
PLoS One; 2012; 7(3):e33101. PubMed ID: 22412987
[TBL] [Abstract][Full Text] [Related]
30. Spinal cord injury induces lesional expression of the proinflammatory and antiangiogenic cytokine EMAP II.
Mueller CA; Schluesener HJ; Conrad S; Meyermann R; Schwab JM
J Neurotrauma; 2003 Oct; 20(10):1007-15. PubMed ID: 14588117
[TBL] [Abstract][Full Text] [Related]
31. Endothelial-monocyte-activating polypeptide II increases blood-tumor barrier permeability by down-regulating the expression levels of tight junction associated proteins.
Xie H; Xue YX; Liu LB; Liu YH
Brain Res; 2010 Mar; 1319():13-20. PubMed ID: 20083091
[TBL] [Abstract][Full Text] [Related]
32. Endothelial-monocyte activating polypeptide II disrupts alveolar epithelial type II to type I cell transdifferentiation.
Chen Y; Legan SK; Mahan A; Thornton J; Xu H; Schwarz MA
Respir Res; 2012 Jan; 13(1):1. PubMed ID: 22214516
[TBL] [Abstract][Full Text] [Related]
33. Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome.
Tandle AT; Calvani M; Uranchimeg B; Zahavi D; Melillo G; Libutti SK
Exp Cell Res; 2009 Jul; 315(11):1850-9. PubMed ID: 19362550
[TBL] [Abstract][Full Text] [Related]
34. Serum endothelial monocyte-activating polypeptide-II: a novel biomarker in patients with non-small-cell lung cancer.
Sen E; Ulger F; Kaya A; Akar N; Gonullu U
Clin Lung Cancer; 2008 May; 9(3):166-70. PubMed ID: 18621627
[TBL] [Abstract][Full Text] [Related]
35. Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells.
Tandle AT; Mazzanti C; Alexander HR; Roberts DD; Libutti SK
Cytokine; 2005 Jun; 30(6):347-58. PubMed ID: 15935955
[TBL] [Abstract][Full Text] [Related]
36. Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature.
Kayton ML; Libutti SK
Curr Opin Investig Drugs; 2001 Jan; 2(1):136-8. PubMed ID: 11527006
[TBL] [Abstract][Full Text] [Related]
37. Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis.
Murray JC; Heng YM; Symonds P; Rice K; Ward W; Huggins M; Todd I; Robins RA
J Leukoc Biol; 2004 May; 75(5):772-6. PubMed ID: 14982944
[TBL] [Abstract][Full Text] [Related]
38. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
[TBL] [Abstract][Full Text] [Related]
39. Expression of endothelial monocyte-activating polypeptide II in the rat dental follicle and its potential role in tooth eruption.
Liu D; Wise GE
Eur J Oral Sci; 2008 Aug; 116(4):334-40. PubMed ID: 18705801
[TBL] [Abstract][Full Text] [Related]
40. Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion.
van Horssen R; Rens JA; Brunstein F; Guns V; van Gils M; Hagen TL; Eggermont AM
Int J Cancer; 2006 Sep; 119(6):1481-90. PubMed ID: 16615114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
